Table GPS-9. Lifetime prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State

Country

Geographical area

Ref.

Year

Age range young adults

Sample size young adults

Cannabis (%)

Cocaine (%) (1)

Amphetamines (%) (2)

Ecstasy (%)
(3)

LSD (%)

Belgium

National

5

2001

15-34

2758

19.2

 

4.0

 

 

Czech Republic

National

1

2002

18-34

1002

38.0

 

4.3

8.8

4.7

Denmark

National

3

2000

16-34

4141

44.6

4.5

9.6

2.6

1.3

Germany

National

6

2003

18-34

3775

36.1

5.0

5.4

5.3

3.4

Estonia

National

2

2003

 

646

 

 

 

 

 

Greece

National (except Aegean and Ionian Islands)

3

2004

15-34

2620

10.8

1.0

0.2

0.6

0.4

Spain

National

4

2001

15-34

6915

35.0

7.7

4.8

7.9

 

France

Metropolitan France

5

2002

15-34

724

39.9

3.0

0.1

1.9

1.5

Ireland

National

4

2002-03

15-34

 

24.4

4.8

4.9

7.1

4.6

Italy

National

2

2003

15-34

5231

29.9

6.2

2.0

3.3

3.0

Cyprus

National

1(4)

2003

15-34

580

24.5

1.4

0.3

5.9

0.3

Latvia

National

1

2003

15-34

 

19.6

1.9

5.3

5.0

2.2

Luxembourg

National

1

1998

15-34

 

15.8

0.3

 

1.9

1.3

Hungary

National

2

2003

18-34

2319

17.4

1.5

4.5

5.6

3.1

Netherlands

National

2

2001

15-34

6687

31.5

5.1

5.1

7.4

1.6

Malta

National

1

2001

 

 

 

 

 

 

 

Poland

National

1

2002

16-34

 

14.7

1.3

4.1

1.5

2.5

Portugal

National

1

2001

15-34

6406

12.4

1.3

0.6

1.4

0.6

Slovakia

National

1

2002

18-34

 

26.9

2.2

1.7

3.9

 

Finland

National

5

2002

15-34

1240

22.4

1.5

4.1

3.4

1.7

Sweden

National

5

2004

18-34

2985

21.0

 

 

 

 

United Kingdom

Northern Ireland

6

2002-03

15-34

 

25.0

2.9

7.0

11.5

7.7

United Kingdom

England and Wales

8

2003-04

16-34

8590

43.4

11.6

18.4

13.6

9.2

Norway

National

1

1999

15-34

794

20.9

3.3

5.4

2.5

 

Notes: 

(1) Cocaine any form. 

(2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine+ecstasy. 

(3) For Spain: ecstasy and other designer drugs. 

(4) Results of this survey should be viewed with caution due to important discrepancies with previous surveys and school surveys results. A new survey with a bigger sample is being conducted in 2005.  

This table aims to present national surveys. Exceptionally some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or big regions with urban and rural areas). Athens was included as reference point for 1993 survey. 

In surveys with small sample sizes results should be interpreted with caution. 

Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

For methods and definitions on population surveys in general, see [Methods and definitions - prevalence and patterns of drug use in the general population]

Sources: 

See [Table GPS-0]

Data filter | gpstab10-en.xml